D and placebo groups) after six-months supplementation are included; inclusion criteria, pancreatic sufficiency or disease status of participants are not defined. There were no significant differences in primary or secondary outcomes in either study. The studies are not directly comparable due to differences in supplementation, outcome reporting and possibly participant characteristics (eg severity of lung disease, growth and nutrition, pancreatic sufficiency). There were no adverse events in either study. The third study (abstract only) compared daily calcitriol (0.25 or 0.5 micrograms) with placebo in pancreatic insufficient children and young adults, only preintervention data were available.
Authors' conclusions
There is no evidence of benefit or harm in the limited number of small-sized published trials. Adherence to relevant CF guidelines on vitamin D should be considered until further evidence is available.
P L A I N L A N G U A G E S U M M A R Y

The use of regular vitamin D preparations for children and adults with cystic fibrosis
Cystic fibrosis with pancreatic insufficiency can cause vitamins, such as vitamin D, to be inadequately absorbed leading to vitamin deficiencies. Lack of vitamin D (vitamin D deficiency) can cause specific problems such as bone deformity and bone fractures. It can also be associated with poorer general and respiratory health. Thus, people with cystic fibrosis are usually given regular vitamin D preparations from a very young age. However, excess vitamin D can also cause respiratory problems and problems with high calcium levels. The review contains three trials, but we could only extract data from two trials. We found no evidence to show whether giving vitamin D regularly to people with cystic fibrosis is beneficial or not. The authors are unable to draw any conclusions regarding the routine administration of Vitamin D supplements and recommend that until further evidence is available, local guidelines are followed regarding this practice.
B A C K G R O U N D
Please note: a glossary of medical terms used in this review is available in the appendices (Appendix 1).
Description of the condition
Cystic fibrosis (CF) is a genetic disorder that affects multiple organs. The dominant symptoms of CF are that of the respiratory and gastrointestinal (GI) systems (Wagener 2003) . In a subgroup of people with CF, the GI system, liver dysfunction, intestinal obstruction and exocrine pancreatic insufficiency are the major issues. Pancreatic insufficiency affects up to 90% of people with CF, whereby fat malabsorption occurs and pancreatic enzyme replacement is required to prevent steatorrhoea and malnutrition (Dodge 2006) . Fat soluble vitamins (A, D, E and K) are co-absorbed with fat and thus deficiency of these vitamins may occur. European and US guidelines recommend routine supplementation of these vitamins (Borowitz 2002; Sinaasappel 2002) . Vitamin D with parathyroid hormone (PTH) regulates serum calcium and phosphate, maintaining adequate concentrations for bone mineralization (Dimitri 2007; Holick 2007) . Vitamin D deficiency may present as symptomatic hypocalcaemia with tetany, seizures or myopathy during early childhood, particularly in exclusively breast-fed infants (Dimitri 2007; Wharton 2003) or as a range of bone deformities (rickets, kypho-scoliosis) or other effects such as delayed closure of anterior fontanelle, dentition problems (delayed eruption of teeth and enamel hypoplasia) (Dimitri 2007; Joiner 2000; Wharton 2003) . Radiological changes of rickets include metaphyseal widening with cupping, splaying and fraying (Dimitri 2007; Joiner 2000; Wharton 2003) . Generalised osteopenia may be an incidental X-ray finding of vitamin D deficiency in an asymptomatic child (Joiner 2000) . Vitamin D deficiency after completion of skeletal growth or growth plate fusion causes osteomalacia without skeletal deformity due to unmineralised osteoid replacing mineralised bone as part of normal bony remodeling; Xrays demonstrate generalised osteopenia (Holick 2007) . This bone is more likely to fracture with poor healing (Holick 2007). Diffuse bone pain accompanies osteomalacia in some adults (Holick 2007) . Vitamin D may also have extra-skeletal effects. Epidemiological studies have also described a link between hypovitaminosis D and lung function (Black 2005) ; and plausible biological reasons include the effect of vitamin D on immunity and oxidative stress (Wright 2005) . However, excessive high doses of vitamin D can also cause problems, albeit this rarely occurs. The effects of vitamin D toxicity are generally non-specific and include nausea, vomiting, poor appetite, constipation, weakness, and weight loss (Chesney 1989; NIH 2007) . It can also cause hypercalcaemia leading to confusion, arrhythmia, and calcinosis (Chesney 1989; NIH 2007) . As ultraviolet B radiation exposure results in the production of vitamin D3, vitamin D levels are likely seasonal.
Description of the intervention
Different vitamin D preparations are available; the D2 preparation has been the main form given and available as a pharmaceutical preparation. However, both vitamins D2 and D3 are available as supplementations and may vary in its efficacy for maintaining serum concentrations of 25 (OH) D. These are prepared by different methods and occur naturally in different foods. Deficiencies may occur from the disease process of CF and insufficient supplementation. Also vitamin D deficiency is increasingly reported even in people without medical risk factors of vitamin D deficiency. Nevertheless vitamin toxicity may also occur from excess supplements. Vitamin D deficiency may lead to specific symptoms and signs, as well as to other nutritional issues, and influence the general well-being and respiratory status (Dodge 2006; Sethuraman 2006) . A Cochrane Systematic Review of vitamin A supplementation has already been published (O'Neil 2007) . Vitamin E and K supplementation will be addressed in other Cochrane Reviews. This review will evaluate vitamin D supplementation.
How the intervention might work
Why it is important to do this review
O B J E C T I V E S
To determine if vitamin D supplementation in children and adults with CF:
1. reduces the frequency of vitamin D deficiency disorders; 2. improves general and respiratory outcomes; 3. increases the frequency of vitamin D toxicity.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised (RCTs) and quasi-randomised trials (controlled clinical trials).
Types of participants
Children or adults with CF (defined by sweat tests or genetic testing), with and without pancreatic insufficiency.
Types of interventions
All preparations of oral vitamin D used as a supplement compared to placebo or no supplementation at any dose and for any duration. Any preparation containing supplemental vitamin D was included.
Types of outcome measures
Primary outcomes 1. Bone mineral density or Vitamin D specific deficiency outcomes i) osteopenia (defined on dual energy X-ray absorptiometry (DXA) scans as T score between -1.0 and -2.5 standard deviations (SD) compared to a reference population (World Health Organization 1994) ii) osteoporosis (defined on DXA scans as T score less than or equal to -2.5 SD compared to a reference population (World Health Organization 1994) iii) severe osteoporosis (defined on DXA scans as T score less than or equal to -2.5 SD and with one or more fragility fractures compared to a reference population (World Health Organization 1994) 2. Growth and nutritional status (weight Z score) 
Searching other resources
We scanned the references in the papers of the included studies for further relevant papers.
Data collection and analysis
Selection of studies
From the title, abstract, or descriptors, both authors independently reviewed results of the literature searches, identifying relevant studies according to the inclusion criteria for further assessment. From these studies, the same two authors independently examined the papers in further detail to select studies for inclusion using the stated criteria. There was no disagreement between authors. It was planned that any disagreement would have been settled by discussion and consensus would have been achieved.
Data extraction and management
The authors reviewed studies that satisfied the inclusion criteria for the review and recorded the following information, where available:
• study setting;
• year of study;
• source of funding;
• participant recruitment details (including number of eligible participants);
• latitude where study was conducted;
• parathyroid hormone;
• trial inclusion and exclusion criteria;
• randomisation and allocation concealment method;
• numbers of participants randomised;
• blinding (masking) of participants, care providers and outcome assessors;
• dose and type of intervention;
• duration of therapy; • co-interventions;
• numbers of participants not followed up;
• reasons for withdrawals from study protocol (clinical, side effects, refusal and other);
• side effects of therapy;
• whether intention-to-treat analyses were possible.
The authors extracted data on the outcomes described above and were evaluated based on 1. short term (12 months or less), and 2. medium to long term (over one year) We planned to extract data relevant for outcomes at one month, up to three months, up to six months, up to twelve months and annually thereafter. We planned to consider including outcome data of differing time periods. The duration of included studies ranged from nine to twelve months, thus this review reports only short term outcomes (up to twelve months).
Assessment of risk of bias in included studies
In order to assess the risk of bias for each of the included studies, the two review authors independently assessed the quality of included studies according to the Cochrane risk of bias tool (Higgins 2011).
Allocation concealment
Authors assessed allocation concealment in each study as follows:
1. Low risk of bias, if the allocation of participants involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed opaque envelopes;
2. Unclear risk of bias, if the method used to conceal the allocation was not described;
3. High risk of bias, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised.
Generation of the allocation sequence
Authors graded each study for generation of allocation sequence as follows:
1. Low risk of bias, if methods of randomisation included use of a random number table, computer-generated lists or similar methods;
2. Unclear risk of bias, if the trial was described as randomised, but no description of the methods used to allocate participants to treatment group was described; 3. High risk of bias, if methods of randomisation included alternation; the use of case record numbers, dates of birth or day of the week, and any procedure that is entirely transparent before allocation.
Blinding (or masking)
Authors graded each study for blinding as follows:
1. blinding of clinician (person delivering treatment) to treatment allocation; 2. blinding of participant to treatment allocation; 3. blinding of outcome assessor to treatment allocation. The more people blinded to an intervention, the lower the authors judged the risk of bias to be.
Follow up
Authors graded each study as to whether numbers of and reasons for dropouts and withdrawals in all intervention groups were described; or if it was specified that there were no dropouts or withdrawals. We have reported on whether the investigators performed a sample-size calculation and if they used an intention-to-treat (ITT) analysis. The risk of bias is higher for lower follow-up rates.
Selective outcome reporting (or reporting bias)
Authors graded each study for selective outcome reporting based on all available results as follows:
1. Low risk of selective outcome reporting if all defined outcomes for each study participant were reported; 2. Unclear risk of selective outcome reporting if it study authors did not provide evidence of or report results for all defined outcomes in study participants;
3. High risk of selective outcome reporting if incomplete reporting or intention to report results of defined outcomes for all enrolled participants.
Measures of treatment effect
The authors included the results from studies meeting the inclusion criteria and which reported any of the outcomes of interest in the subsequent meta-analyses. For dichotomous outcome variables of each individual study, we planned to calculate the odds ratio (OR) using a modified ITT analysis, i.e. if ITT analysis was not used by the original investigators, dropouts were considered treatment failures. We would have calculated the summary odds ratios and 95% confidence intervals (CIs) (fixed-effect model) using the Cochrane Collaboration's statistical package (RevMan 5). Numbers needed to treat (NNT) and their 95% CIs were to be calculated from the pooled OR and its 95% CI for a specific baseline risk, which is the sum of all the events in the control groups (in all trials) divided by the total participant numbers in control groups in all trials using an online calculator (Cates 2003) . For continuous outcomes, we recorded the mean change from baseline for each group or mean post-treatment or post-intervention values and standard deviation. Post-intervention standard deviations were calculated, if not reported, from the reported mean difference between groups (intervention and control) and 95% confidence intervals using the formulae detailed in Revman (RevMan 5). If standard errors had been reported, we planned to convert these to standard deviations. We then calculated a pooled estimate of treatment effect by the mean difference and 95% confidence interval (fixed-effect model) again using RevMan (RevMan 5).
Unit of analysis issues
The identified cross-over study published only baseline data, thus an analysis including the planned fixed-effect generic inverse variance (GIV) analysis in RevMan, summary weighted differences and 95% CIs (RevMan 5) was not possible.
Dealing with missing data
The authors requested further information from the primary investigators of two studies (Brown 2005; Haworth 2004 ). We re-ceived a response from Haworth, but not from Brown; no additional information could be obtained.
Assessment of heterogeneity
Where possible we have combined study results with the same outcome measure, described heterogeneity between study results and used chi-squared test to determine any statistically significant difference. Heterogeneity was considered to be significant with a P value less than 0.10 (Deeks 2011). We also used the I 2 statistic, with heterogeneity categorised such that a value of under 25% was considered low, around 50% moderate and over 75% a high degree of heterogeneity (Higgins 2003).
Assessment of reporting biases
We had planned to assess publication bias using a funnel plot and analysed the included trials for selective reporting. We were unable to produce any funnel plots as there were insufficient studies i.e. less than 10. However, asymmetry in a funnel plot may be due to other reasons such as heterogeneity and reporting biases.
Data synthesis
We used a fixed-effect model in the analysis. A random-effects model was planned if there had been concerns regarding statistical heterogeneity (I 2 higher than 50%).
Subgroup analysis and investigation of heterogeneity
The planned subgroup analyses (children and adults, formulation of vitamin D, previous bowel resection, pancreatic insufficiency, method of CF diagnosis, gender and latitude bands) to investigate heterogeneity were not possible because there were too few trials included in the review.
Sensitivity analysis
Sensitivity analysis either by random-effects model or by "treatment received" was not possible because of the insufficient number of included studies in this review.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of studies awaiting classification. The data from the third study were not able to be included as only baseline BMD and markers of bone turnover in pancreatic insufficient children and young adults prior to two years of calcitriol supplementation (0.25 mcg if the participant weighed under 45 kg, 0.5 mcg if the participant weighed 45 kg and over) and some narrative adverse event information were reported (Brown 2005).
Results of the search
Excluded studies
Two studies were excluded due to interventions not forming part of this review -bisphosphate and ultraviolet (UV) B radiation (Aris 2000; Gronowitz 2003).
Risk of bias in included studies Allocation
There were no details given on method of generation of allocation sequence or its concealment in any of the included studies, although one study does state that participants were randomised by gender and age (8 to 10, 11 to 14, 15 to 18 years) to stratify for pubertal status (Brown 2005 
Incomplete outcome data
No data are available for any outcomes in one study (Brown 2005 
Selective reporting
In the Popescu study, data are reported after only 9 months of a 36-month study, we therefore judge this study to have a high risk of selective reporting (Popescu 1998). We did not identify any selective reporting in the other two included studies and judge there to be a low risk of bias from this for these studies (Brown 2005; Haworth 2004 ).
Other potential sources of bias
We did not identify any other potential sources of bias in any of the studies (Brown 2005; Haworth 2004; Popescu 1998) .
Effects of interventions
No data could be combined as the studies presented results in different formats. Thus sensitivity analyses, subgroup analyses or assessment of heterogeneity could not be undertaken for this version of the review.
Primary outcomes 1. Bone mineral density or Vitamin D-specific deficiency outcomes
There was no available data on the primary outcome from any study.
Growth and nutritional status (weight z score)
No study reports weight Z score (Brown 2005; Haworth 2004; Popescu 1998) .Two studies reported baseline BMI but did not report either any follow up or end of intervention data or any change in BMI (Brown 2005; Haworth 2004 ). Popescu reports no growth or nutritional status measures (Popescu 1998).
Secondary outcomes 1. Other vitamin D-related deficiency disorders
a. fractures
This outcome was not reported in any of the included studies.
b. tetany
c. rickets
d. other radiological abnormality
e. measured levels of calcium and vitamin D (25-hydroxyvitamin D (25 (OH) D) or 1.25-dihydroxyvitamin D (1.25 (OH) D))
One study (Haworth 2004) reported data on serum calcium which showed no difference between groups (Analysis 1.1). Two studies reported data for vitamin D (25 (OH) D), one at nine months (Popescu 1998) and one at 12 months (Haworth 2004) and one study reported data for vitamin D (1,25 (OH) D) at nine months (Popescu 1998). We were able to combine the data for vitamin D (25 (OH) D) and have presented all data in the meta-analysis, but no significant differences between groups were reported. For 25 (OH) D, the mean difference between groups was -2.79 pg/ ml (95% confidence interval (CI) -7.25 to 1.6) (Analysis 1.2); for 1,25 (OH) D the mean difference was -3.50 pg/ml (95% CI -22.51 to 15.510 (Analysis 1.3).
Respiratory outcomes
a. bronchiectasis severity control
b. lung function indices
All three included studies reported lung function indices at baseline only (Brown 2005; Haworth 2004; Popescu 1998) .
c. proportions of participants who had respiratory exacerbations or hospitalisations or both
e. total number of hospitalised days
f. other objective indices
Quality of life
Adverse events
Two studies did not report any adverse outcomes from either group of participants (Haworth 2004; Popescu 1998) . One of the abstracts reported that two participants (one in each group) developed nephrolithiasis; furthermore one participant in the treatment group developed mild hypercalcaemia and two participants in the placebo group had hypercalciuria (Brown 2005). We could not present this data in the analysis as we could not ascertain from the abstract how many children were in each arm of the study.
Parathyroid hormone levels
Two studies reported on this outcome, but we were unable to combine the data since one reported an absolute value at the end of the study (Popescu 1998) and the other reported change in parathyroid hormone levels after 12 months intervention (placebo or supplementation) (Haworth 2004) . Neither study reported any significant difference between groups (Analysis 1.4; Analysis 1.5).
Post-hoc analysis
We include a post-hoc analysis of mean bone mineral density scores (z scores) which were reported in two studies (Haworth 2004; Popescu 1998) . No data could be combined: Popescu reported per cent change in whole body mineral bone content, mean difference (MD) -3.00% (95% CI -13.63 to 7.63) (Analysis 2.1) and lumbar spine z score at nine months (six months of treatment and a three-month washout period), MD -0.24 (95% CI -1.27 to 0.79) (Analysis 2.2) (Popescu 1998); and Haworth reported per cent change in bone mineral density after 12 months of treatment measured in the lumbar spine, MD 1.90 (95% CI -0.90 to 4.70) ()Analysis 2.3; the hip, MD 0.70 (95% CI -2.20 to 3.60) (Analysis 2.4); and the distal forearm, MD 1.70 (95% CI -2.20 to 5.60 (Analysis 2.5) (Haworth 2004) . For all the available outcomes, there was no significant difference between the groups. Bone mineral density z score do not meet the primary bone mineral density outcome measures of this review, but are an objective and reproducible assessment of intervention effect (Analysis 2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4; Analysis 2.5).
D I S C U S S I O N
Daily vitamin D supplementation is almost universally recommended for people with CF who are pancreatic insufficient (Borowitz 2002; Sinaasappel 2002; UK CF Trust 2007) . In this review we attempted to evaluate the effect of vitamin D supplementation compared with placebo on the frequency of vitamin D deficiency, including BMD, growth and nutrition, respiratory status, biochemical markers of bone metabolism in children and adults with CF. However, it is unfortunate that there were only three small controlled studies that have examined this comparison and only two which have published any post-treatment data. Also the studies used different formulations of vitamin D.
Summary of main results
There was no clear benefit or harm identified with short-term vitamin D supplementation compared to placebo in the 41 people with CF completing the period of intervention in the two studies with available data (Haworth 2004; Popescu 1998) . This number excludes one study which has only been published as an abstract and only contains baseline data and narrative information on adverse events (Brown 2005) . This study reports adverse events in 6 out of 54 participants; nephrolithiasis occurred in two (placebo and calcitriol), mild asymptomatic hypercalcaemia in one receiving calcitriol, hypercalciuria in two receiving placebo, and hyperphosphataemia in one receiving placebo (Brown 2005) . No adverse events occurred in the full publication included in this review (Haworth 2004) .
Overall completeness and applicability of evidence
The three studies meeting inclusion criteria provided data for assessment of the efficacy of short-term (up to 12 months) vitamin D supplementation on BMD in a small number of children and adults with CF. There were no data on the effects of supplementation on growth and nutrition. No conclusions about the longer term effects of vitamin D supplementation, either beneficial or harmful, can be drawn due to the short-term nature of supplementation and follow up. All participants in the Haworth study continued the centre's routine vitamin D supplement of 900 IU daily (Haworth 2004) . This was in keeping with the UK guidelines (UK CF Trust 2007) and may not be standard practice in all centres. Many of the secondary outcomes (effect of vitamin D supplementation on the frequency of clinical markers of vitamin D deficiency, respiratory outcomes and quality of life) were not assessable from data in any study which limits the external validity of the outcomes. No study provided information to address potential confounders during the study period, including measures of pancreatic sufficiency or adequacy of pancreatic enzyme replacement in pancreatic-insufficient participants; the season, latitude and ethnicity of participants (which will directly impact on 25-OHD levels and thus BMD); the amount of weight-bearing activity; respiratory status; or frequency of illness. These factors limit the generalisability of these results to other CF populations.
Quality of the evidence
This review includes only three small studies of short term vitamin D supplementation with BMD (either as percent change or z score) the only consistently reported primary outcome measure. The lack of information regarding methods used to diagnose CF; respiratory and disease status, growth and nutrition during the study; and the adequacy of exocrine pancreatic function or enzyme replacement restrict the generalisation of each study's findings to the general CF population. All relevant studies are likely to have been identified by our search methods. Two papers were abstracts and thus assessment was limited (Brown 2005; Popescu 1998) .
Potential biases in the review process
The two authors' independent review of included studies and data extraction minimised the potential for additional bias beyond that detailed in the risk of bias tables. Neither of the authors have any conflict of interest.
A U T H O R S ' C O N C L U S I O N S Implications for practice
There is a lack of published data on the effect of vitamin D supplementation, including benefits and adverse effects, in people with CF. The data, which are limited by very small numbers, showed no benefit or harm in the supplemented group. Until further studies are available, adherence to relevant guidelines on supplementation with vitamin D and calcium, such as the UK guidelines (UK CF Trust 2007), should be considered. Toxicity is an uncommon occurrence in the small number of published randomised, controlled studies of vitamin D supplementation. Further randomised controlled trials are clearly required.
Also it is biologically plausible that currently, with improved pancreatic replacement therapies and attention to macro nutrition and caloric supplements, the majority of people with CF are vitamin D sufficient and may not require daily vitamin D supplementation. Daily supplementation in these situations at best causes no harm, but adds a further burden to the daily medical regimen of people with CF.
Implications for research
The available data suggest the CF population have lower vitamin D levels and bone mineral density than age and gender-matched unaffected individuals, but this is likely to be multifactorial (e.g. malabsorption, chronic illness, pubertal delay, reduced activity particularly weight bearing activity and medications impairing physiological bone remodeling) which may not necessarily be overcome by supplementation. Parallel randomised controlled trials of vitamin D supplementation in CF are required and should take into account the effects of pubertal stage, latitude and season, ethnicity, severity of lung disease and adequacy of enzyme replacement in pancreatic-insufficient patients. Future studies may also need to take broad genetic mutations groups (such as 508 or not) into account although this likely increases the complexity of the study.
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C H A R A C T E R I S T I C S O F S T U D I E S
Low risk 1 study withdrawal due to pregnancy in intervention group, although this wasn't a specified exclusion criteria. Thus good follow-up rate (97%) All others enrolled completed study period.
Selective reporting (reporting bias) Low risk All defined outcomes are reported.
Other bias Unclear risk All subjects were participants of a longitudinal BMD study preceding this study Only 31/55 eligible participants enrolled, no specifics given for those who declined to participate
Popescu 1998
Methods Double-blind, randomised, cross-over study.
Participants 22 children with CF (mean 9.3 years, range 6.1 -12.2 years). No disease status indicators reported -authors comment that all were "mildly affected"
Interventions Supplementation with 1g calcium, 1600 IU vitamin D, 1g calcium and 1600 IU vitamin D and placebo each for 6 months with a 3-month washout period between interventions Outcomes Outcomes reported at baseline and at 9 months (after 6 months of intervention and 3 month washout period): BMD (lumbar spine, femoral neck, distal radius and whole body; method not described) Outcomes reported at baseline and at 6 months of supplementation: serum and urine chemistry, 25-OHD, 1,25-(OH) 2 D, PTH, bone turnover markers (osteocalcin, bone specific alkaline phosphatase)
Characteristics of studies awaiting assessment [ordered by study ID]
Hillman 2008
Methods Double-blinded randomized cross-over trial with 4 arms. Single centre in USA Participants 15 children aged 7 to 13, remained on standard medication (including pancreatic enzymes and ADEK vitamins). Children on oral or glucocorticoids were excluded
Interventions 4x 6 month treatments (including placebo) with 3-month washout period between each Placebo vs calcium (1g) 
